Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients ≥ 65 years of age with a clinical diagnosis of essential hypertension at Visit 1.
Mean sitting SBP (MSSBP) ≥ 140 mmHg and \< 180 mmHg at Visit 2/Visit 201 and Visit 3.
Absolute MSSBP difference ≤ 20 mmHg between Visit 3 and the Visit immediately prior
You may not be if
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
Severe hypertension (MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg) at Visit 1, Visit 2, Visit 201 or Visit 3 or during patient self measured blood pressure (SMBP) monitoring in the pre-randomization period confirmed by office measurement.
Current treatment with any blocker of the renin angiotensin aldosterone system (RAAS) (aliskiren, ACE inhibitor, angiotensin receptor blocker or an aldosterone antagonist) and unable to discontinue this therapy.
Concurrent use of any anti-hypertensive medications except a stable dose of 3 months prior to Visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g., tamsulosin \[Flomax®\] for benign prostatic hypertrophy), beta blockers for angina, or beta blocker ophthalmic preparations.
Clareo Health | Aliskiren Study of Safety and Efficacy in Senior Hypertensives
